Announcements Trials
Browse Landscape

Phase

Phase 3 21Phase 2 13Phase 4 4Phase 1/2 2Phase 1 2Phase NA 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 4

Interventions

Letrozole 6Tamoxifen 4Cisplatin 4Anastrozole 4ribociclib 3exemestane 3Vancomycin 3Specimen Handling 3Nivolumab 3Magnetic Resonance Spectroscopy 3Human Papillomavirus Recombinant Vaccine nonavalent 3Dexamethasone 3Carboplatin 3Bevacizumab 3trametinib 2toripalimab 2encorafenib 2dabrafenib 2binimetinib 2atezolizumab 2asciminib 2Vincristine 2Sodium Chloride 2Rituximab 2Prednisone 2Papillomavirus Vaccines 2Methotrexate 2Medroxyprogesterone Acetate 2Lenalidomide 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 4 × Anastrozole × 90 days × Clear all
NCT01127295 2026-04-14

PHACS

Institut Claudius Regaud

Phase 4 Completed
2,000 enrolled
Breast

Breast Neoplasms

NCT01553903 2026-04-14

OXYTAM

Institut Claudius Regaud

Phase 4 Completed
29 enrolled
Breast

Breast Neoplasms

NCT01612871 2026-04-14

MIRHO

Institut Claudius Regaud

Phase 4 Completed
39 enrolled
Breast

Breast Neoplasms

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Novartis

Phase 4 Active not recruiting
134 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡